Publications
50
Citations
733
Est. group size
—
Recurring co-author estimate
Active years
61
Publishing since 1966
Kevin Booth's research focuses on clinical trials for Alzheimer's disease treatments, particularly experimental drugs and vaccines such as bapineuzumab and ACC-001 aimed at slowing or reversing the disease. The work involves testing the safety, tolerability, and biological markers of these therapies in patients with mild to moderate Alzheimer's disease. Much of the output centers on large, randomized phase 2 and phase 3 trials and their long-term extensions.
Publication activity appears low and intermittent over the last decade, with most output clustered around 2016-2018 and only sporadic publications since, averaging under one per year in the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~22 · 0% small-team papers (≤3 authors) · across 7 venues
- Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Neurology · 2018
- Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research · 2017
- Additional file 4: Table S1. of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 4: Table S1. of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 5: of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 6: of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 3: of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâ s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 6: of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 3: of Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Additional file 2: of Bapineuzumab for mild to moderate Alzheimerâ s disease in two global, randomized, phase 3 trials
Figshare · 2016
- Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Alzheimer s Research & Therapy · 2016
- Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies
Alzheimer s Research & Therapy · 2016
- VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDY
The Journal of Prevention of Alzheimer s Disease · 2016
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease
Journal of Alzheimer s Disease · 2016
- Figshare×16
- Alzheimer s Research & Therapy×2
- Genetics in Medicine Open×2
- Neurology×1
- Current Alzheimer Research×1
- Kelley Faber
Medicine · Indiana University
- Irving E. Vega
Medicine · University of Michigan
- Karen Crawford
Medicine · Indiana University
- Bernardino Ghetti
Medicine · Indiana University
- Kelly Nudelman
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile